<DOC>
	<DOCNO>NCT00217295</DOCNO>
	<brief_summary>This clinical trial relapsing-remitting Multiple Sclerosis determine Topamax add Avonex neuroprotective effect measure brain parenchymal fraction ( measure brain shrinkage ) clinical assessment score evaluate disease progression .</brief_summary>
	<brief_title>A Safety Study Combination Treatment With Avonex Placebo-Controlled Dosing Topamax Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>The protocol require participant treat Avonex addition patient blindly assign either group receive Topamax placebo control . Repeated neurological clinical examination perform laboratory test determine possible adverse drug effect . The scaled neurologic examination ( EDSS MSFC ) brain MRI 's do regular interval evaluate possible treatment effect .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Relapsingremitting multiple sclerosis Secondary progressive multiple sclerosis Contraindication MRI Systemic disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Relapsing-remitting multiple sclerosis</keyword>
	<keyword>Brain atrophy</keyword>
	<keyword>Disease progression</keyword>
</DOC>